In case you missed it: November 14 to November 18
Take a look back at this week's top news stories.
Chemical hair straightening may increase uterine cancer risk
A new NIH study found women who used chemical hair straightening products to be at a higher risk for uterine cancer than women who didn’t use these products.
FDA approves IUD to prevent pregnancy for up to 8 years
The Food and Drug Administration (FDA) has approved Medicine360’s supplemental new drug application to extend the use of its levongestrel-releasing intrauterine system 52mg (LILETTA) to prevent pregnancy for up to 8 years.
A new possible solution to vaginal odor?
Alyssa Dweck, MD, discusses some recent positive data presented at the 2022 NAMS meeting regarding Clairvee (Bonafide Health) as a potential treatment for vaginal odor.
Iranian hackers emerge as cyberthreat to health care computer networks
‘Charming Kitten’ believed to be a front for Islamic Revolutionary Guard Corps, according to HHS’ cybersecurity agency.
Daré Bioscience announces grant to develop vaginal thermosetting gel for delivery of live biotherapeutics
Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for ovarian cancer
This is the first FDA-approved ADC for platinum-resistant disease, according to ImmunoGen.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.